Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

Mallawaarachchi, Sumudu Rasangi; Amminger, G Paul; Farhall, John; Bolt, Luke K; Nelson, Barnaby; Yuen, Hok Pan; McGorry, Patrick D; Markulev, Connie; Schäfer, Miriam R; Mossaheb, Nilufar; Schlögelhofer, Monika; Smesny, Stefan; Hickie, Ian B; Berger, Gregor Emanuel; Chen, Eric Y H; de Haan, Lieuwe; Nieman, Dorien H; Nordentoft, Merete; Riecher-Rössler, Anita; Verma, Swapna

doi:10.1016/j.schres.2020.03.008

Citations

Citation copied

Mallawaarachchi, S. R., Amminger, G. P., Farhall, J., Bolt, L. K., Nelson, B., Yuen, H. P., McGorry, P. D., Markulev, C., Schäfer, M. R., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I. B., Berger, G. E., Chen, E. Y. H., de Haan, L., Nieman, D. H., Nordentoft, M., Riecher-Rössler, A., … Allott, K. A. (2020). Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. Schizophrenia Research, 218, 48–54. https://doi.org/10.1016/j.schres.2020.03.008

Abstract

Neurocognitive impairments are well established in both ultra-high risk (UHR) for psychosis and major depressive disorder (MDD). Despite this understanding, investigation of neurocognitive deficits in UHR individuals with MDD and its association with MDD within this population, has been scarce. Hence, this study aimed to examine any differences in neurocognition at baseline between those with MDD at baseline and those with no history of MDD, as well as determine whether neurocognitive variables are significantly associated with meetin